Pasar al contenido principal

ELIMINACION DEL RESERVORIO LATENTE DEL VIH-1 MEDIANTE EL USO DE CELULAS T MODIFICADAS CON EL RECEPTOR DE ANTIGENO QUIMERICO ANTI-CD4 (ANTICD4-CAR)

PID2020-115931RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Exceptional, naturally occurring HIV-1 control, Insight into a functional cure

  • Salgado, Maria|||0000-0003-1551-7216
  • Migueles, S.A.
  • Yu, X.G.
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Exceptional elite controllers represent an extremely rare group of people with HIV-1 (PWH) who exhibit spontaneous, high-level control of viral replication below the limits of detection in sensitive clinical monitoring assays and without disease progression in the absence of antiretroviral therapy for prolonged periods, frequently exceeding 25 years. Here, we discuss the different cases that have been reported in the scientific literature, their unique genetic, virological, and immunological characteristics, and their relevance as the best model for the functional cure of HIV-1.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir

  • González-Navarro, Irene|||0000-0002-4567-766X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Gálvez, Cristina|||0000-0002-2286-6193
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Bailón, Lucía|||0000-0001-7277-9314
  • Miranda, Cristina
  • García, Felipe|||0000-0001-7658-5832
  • Leal, Lorna|||0000-0001-7887-6027
  • Vandekerckhove, Linos|||0000-0002-8600-1631
  • Marconi, Vincent C.
  • Sekaly, Rafick P.
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
Antiretroviral therapy (ART) has improved the clinical management of HIV-1 infection. However, little is known about how the latest ART recommendations affect the heterogeneity of the HIV-1 reservoir size. We used a complete statistical approach to outline parameters underlying the diversity in HIV-1 reservoir size in a cohort of 892 people with HIV-1 (PWH) on suppressive ART for more than 3 years. Total HIV-1-DNA levels were measured in PBMCs using digital droplet PCR (ddPCR). We classified 179 (20%) participants as being low viral reservoir treated (LoViReT) (<50 HIV-1-DNA copies/10 6 PBMCs). Twenty variables were collected to explore their association with the LoViReT phenotype using machine learning approaches. LoViReT status was closely associated with higher nadir CD4, lower zenith pre-ART viral load, lower CD4 recovery, shorter time from diagnosis to undetectable viral load, and initiation of treatment with an integrase inhibitor-containing (InSTI-containing) regimen. Initiation of ART with any InSTI was also linked with a shorter time to undetectable viremia. Locally estimated scatterplot smoothing (LOESS) regression revealed a progressive reduction in the size of the HIV-1 reservoir in individuals who started ART after 2007. Similarly, a higher nadir CD4 and a shorter time to undetectable viremia were observed when treatment was initiated after that year. Our findings demonstrate that the progressive implementation of earlier, universal treatment at diagnosis and the use of InSTIs affected the size of the HIV-1 reservoir. Our work shows that effective management of infection is the first step toward reducing the reservoir and brings us closer to achieving a cure. NIH; Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), NIH; Merck Sharp & Dohme. In this manuscript, we show that the progressive implementation of earlier, universal treatment at diagnosis and the use of InSTIs affect the size of the HIV-1 reservoir in the population of PWH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs)

  • Gálvez, Cristina|||0000-0002-2286-6193
  • Urrea, Víctor|||0000-0002-2577-856X
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Bernal, Sílvia
  • Benet, Susana|||0000-0002-2219-8826
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Bailón, Lucía|||0000-0001-7277-9314
  • Dalmau, Judith|||0000-0001-7513-3711
  • Martinez, Andrea
  • Nieto Gil-Ortega, Aroa|||0000-0001-8477-5062
  • Leal, Lorna|||0000-0001-7887-6027
  • García, Felipe|||0000-0001-7658-5832
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
HIV cure strategies aim to eliminate viral reservoirs that persist despite successful antiretroviral therapy (ART). We have previously described that 9% of HIV-infected individuals who receive ART harbor low levels of provirus (LoViReTs). We selected 22 LoViReTs matched with 22 controls ART suppressed for more than 3 years with fewer than 100 and more than 100 HIV-DNA copies/10 6 CD4 + T cells, respectively. We measured HIV reservoirs in blood and host genetic factors. Fourteen LoViReTs underwent leukapheresis to analyze replication-competent virus, and HIV-DNA in CD4 + T-cell subpopulations. Additionally, we measured HIV-DNA in rectum and/or lymph node biopsies from nine of them. We found that LoViReTs harbored not only lower levels of total HIV-DNA, but also significantly lower intact HIV-DNA, cell-associated HIV-RNA, and ultrasensitive viral load than controls. The proportion of intact versus total proviruses was similar in both groups. We found no differences in the percentage of host factors. In peripheral blood, 71% of LoViReTs had undetectable replication-competent virus. Minimum levels of total HIV-DNA were found in rectal and lymph node biopsies compared with HIV-infected individuals receiving ART. The main contributors to the reservoir were short-lived transitional memory and effector memory T cells (47% and 29%, respectively), indicating an altered distribution of the HIV reservoir in the peripheral T-cell subpopulations of LoViReTs. In conclusion, LoViReTs are characterized by low levels of viral reservoir in peripheral blood and secondary lymphoid tissues, which might be explained by an altered distribution of the proviral HIV-DNA towards more short-lived memory T cells. LoViReTs can be considered exceptional candidates for future interventions aimed at curing HIV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

  • Campos-Gonzalez, Gerard|||0000-0002-5442-4963
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Salgado, Maria|||0000-0003-1551-7216
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and is becoming a well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells have potential as a therapy to achieve a sterilizing cure for human immunodeficiency virus (HIV) infection. However, translation of this technology to the HIV scenario has not been easy, as many challenges have appeared along the way that hinder the consolidation of CAR-T cells as a putative therapy. Here, we review the origin and development of CAR-T cells, describe the advantages of CAR-T cell therapy in comparison with other therapies, and describe the major obstacles currently faced regarding application of this technology in the HIV field, specifically, viral escape, CAR-T cell infectivity, and accessibility to hidden reservoirs. Nonetheless, promising results in successfully tackling some of these issues that have been obtained in clinical trials suggest a bright future for CAR-T cells as a consolidated therapy.